ROS1 and cancer: When existing separately, activating EGFR mutations are well defined predictive effects of EGFR-TKIs in NSCLC cancer patients, and while coexisting with KRAS mutations and ALK or ROS1 gene rearrangements, the EGFR-TKIs are predicted to be resistant [24].